Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
about
Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesCapsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approachA vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types.Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizingImmunoprevention of human papillomavirus-associated malignanciesA chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.Second-generation prophylactic HPV vaccines: successes and challenges.Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal AntibodiesHPV vaccination for prevention of skin cancer.Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Progress and prospects for L2-based human papillomavirus vaccinesBroad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.Virus-based nanoparticles as platform technologies for modern vaccines.Developments in L2-based human papillomavirus (HPV) vaccines.Current status and future prospects for human papillomavirus vaccines.HPV vaccines: Global perspectives.Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types.Virus like particles as a platform for cancer vaccine development.Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus.Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?
P2860
Q28603888-8D40BAB6-856D-4294-AF88-4F1A58CFF0E9Q28607775-B8FD13D8-12EB-4345-B4C2-87CE8640EE82Q33572691-65EB70CD-26F4-4E8F-B0F5-37E6C38921CFQ33967341-812899C3-63AE-45C9-8B51-2B1B9CC7262CQ35044376-EAB21F35-70D5-40BF-9030-E69B1FB68DB4Q35196119-697C1E82-924B-4A0D-B39F-2A98B0D8F4E8Q35541210-01AA9BF1-A263-492A-8E08-043D68251FB7Q35541886-02AF5F4A-06CF-4C82-8E74-082FABF0EB03Q35744303-6AD03F95-5BDF-4EB1-9E6C-D186A7D7753BQ35773930-73AF476C-5C11-49A5-AD30-FDF06696A491Q35887782-B6D3C61C-8C0E-4388-8102-54CCF1D49FFAQ36240497-2F922EB6-0BBF-4B58-A76B-5E80D444D4C1Q37014047-F03DE574-E643-41EB-A16F-714BC352012EQ37073299-E826CD6B-FD32-485E-A281-3518D3B29D94Q37714750-85149674-545C-4CAE-AA99-C3563D225BA8Q38370782-ADCCA242-BF50-4923-82C1-57EF12BE31ADQ38554795-E4C58618-8377-466E-9FDE-8B474BFCA9EEQ38671633-AEEB0DD7-779F-4248-BECD-AC8B34BF8548Q38702017-F94D7EEC-9A8A-4750-BAF0-F68295DECB74Q39021001-68C7BA45-7F0A-485B-9441-2DEBFBDCC18DQ40056541-C1C9E8BC-F2C8-4F54-BE9E-4FECBEF15783Q40265515-30508845-5E82-40E2-81A8-E329DEFA11FDQ41926367-C5533642-E850-49E9-A60B-A1334FD06944Q45324534-83409359-C52D-4006-B4A7-F804EB743CECQ52312756-83E5FF71-D188-427D-A345-6DD2B7309A45Q54216752-6398691B-61D7-454B-A11D-042CEC5C6295Q55054189-CC049250-C888-4BDB-9A25-04540E093A3D
P2860
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy of RG1-VLP vaccinatio ...... aneous human papillomaviruses.
@en
Efficacy of RG1-VLP vaccinatio ...... aneous human papillomaviruses.
@nl
type
label
Efficacy of RG1-VLP vaccinatio ...... aneous human papillomaviruses.
@en
Efficacy of RG1-VLP vaccinatio ...... aneous human papillomaviruses.
@nl
prefLabel
Efficacy of RG1-VLP vaccinatio ...... aneous human papillomaviruses.
@en
Efficacy of RG1-VLP vaccinatio ...... aneous human papillomaviruses.
@nl
P2093
P2860
P356
P1476
Efficacy of RG1-VLP vaccinatio ...... taneous human papillomaviruses
@en
P2093
Christina Schellenbacher
Christoph Jindra
Dieter Fink
Joakim Dillner
Kihyuck Kwak
Reinhard Kirnbauer
Richard B S Roden
Saeed Shafti-Keramat
P2860
P2888
P304
P356
10.1038/JID.2013.253
P407
P577
2013-05-10T00:00:00Z